http://www.regentherapeutics.com/regen

Consider a company with a market cap of around 10 million which could well in the future be generating revenue well in excess of that figure every year. Interested then read on and DYOR on Regen Therapeutics.

For some time now I have been a shareholder of RGT who have been working with a patented product Colostrinin as a treatment for Alzheimers. Tests so far would seem to indicate that it is a success and they are currently refining a pharmaceutical product.

Meantime they are also pushing forward on the nutraceutical front as tests have shown positive results in respect of mild cognitive disorders (memory loss etc). Further research is being carried out regarding other major illnesses. As at mid 2007 a launch is scheduled in the US for Q4 and there are rumours of an earlier launch in Australia possibly imminent based on the fact that adverts are already starting to appear see:- http://www.quantumevolution.com.au/oscommerce/index.php

They have also acquired a contract research organisation which should mean that research money for clinical trials that had previously been spent will now be kept inside the group.

February 2006 has seen Regen acquire the rights, following a feasibility study, in respect of other uses for a well known drug (Zolpidem) that has undergone phase 2 clinical trials where results are expected around August 2007. The new use relates to the positive effects that have been seen when treating stroke victims with the drug. There has been a lot of press interest which a web search should reveal.

An interview with the chairman (Percy Lomax) in the summer of 2004 talked of a nutraceutical product producing royalty payments of 10% on a possible 100 million sales per annum. The pharmaceutical version which also requires a licensing partner will if successful have projected sales of 1-5 billion again which would generate royalty payments to Regen. I leave you to contemplate just how high the share price would be if this were the case but suffice to say it will be many many times what it is now.

Acquisition (Oct 2004) of Guildford Clinical Pharmacology unit demonstrates not only that they are progressive and expanding but also thinking strategically for GCPUL being a research based company no doubt Regen can now keep such costs within the group whereas before testing had to be paid for elsewhere. This acquisition also means that they have revenue and are therefore no longer a "virtual" company.

A share issue in July 2007 means that they should now have funds in hand to take them through to cash generation. Hopefully this means we have seen the last of the issues excepting any used by way of acquiring profitable companies.

The North America link is an interesting one as perhaps in readiness for the launch of Colostrinin out there Regen set up an ADR programme which became effective in March 2005. ADR's ( American Depositary Receipts) are a way for US investors to buy shares in UK companies. In Regen's case one ADR is equivalent to 200 Regen UK shares so when an ADR is purhased the Bank of New York will buy the proportionate number of UK shares and convert them into ADR's for the investor. At present this is not a factor however with the launch of Colostrinin out there if successful it may mean that US investors will want to be involved in the company and that will have a direct positive impact on our share price. In the US Colostrum (from which Colostrinin is produced )is already a recognised and popular health product and so demand should be good.

So all in all exciting times ahead. There can be few shares around that offer the potential of this one although as always DYOR and good luck with your investments whatever you decide here.

Already up 5.9% this morning

News this week....

ReGen Therapeutics says study shows colostrinin enhances memory in chicks
AFX


LONDON (AFX) - ReGen Therapeutics PLC said a study has shown that colostrinin enhances memory in newly hatched chicks.

This research has been conducted as part of ReGen's ongoing collaboration with the Department of Biological Sciences, Open University, Milton Keynes, UK and has been performed by Professor Michael Stewart and Dr Duncan Banks.

Commenting on the findings, Professor Stewart head of the Department of

Biological Sciences at the Open University, the study's principal investigator

said: 'We have used young chicks as a model system in which to study the effects of Colostrinin on memory formation, together with a single one trial learning paradigm - avoidance of a bitter tasting substance. When administered

intracranially and intraperitoneally, Colostrinin was shown to have a very

strong effect in enhancing memory when compared with control saline injections.

These results may help to explain the clinical benefits seen with Colostrinin

in clinical studies'.

ReGen's principal activity is the development of a potential therapy for

Alzheimer's disease and also the development of neutraceutical uses for

Colostrinin.

Recommended in Shares magazine today. A very positive interview by the Wall Street Journal with the chairman in July and interims in Sept. Looks like some good news could be here soon.

Only news this company seem to announce is another round of fund raising.Never known a company keep coming back to the market. Expenses as a % of money raised is crazy.

Gathering momentum - share price has rise by 25%+ over the last couple of months and the interims in Sept pointed to more news in the fourth quarter. Exciting times ahead. DYOR

Just read that the October edition of Growth investor says:-

"Regen Therapeutics is seriously evaluating an acquisition in the UK, sayschairman percy Lomax. He is also applying to have the AIM quoted companyshares granted a parallel listing on the US Nasdaq small cap market.As for the company's acquisition hopes Lomax is tight lipped about his target.
He say's ReGen has no need to raise cash at present."

I cannot comment on content as have just copied this from elsewhere and don't subscribe to Growth investor. If correct this could be very good news as it will add another string/s to Regens bow. We knew about the US and expected to hear on that soon - but an acquisition?! Percy did say the company would be looking very different soon.

I wonder if this might explain some of the large trades that have gone through of late as someone always seems to know about these things before anyone else.

The online buying limits are getting tighter - people have had trouble even buying 50000 this afternoon and yet you can readily sell up to 250000 for around the mid price so should tick up again soon.

Anybody got their ear to the ground with more info on the growth investor story?

Up almost 10% again today. Now around 50% up in the last couple of months

UP again today - I'm surprised there's not more interest on this site when other BB's are buzzing with RGT

Ended 12% up today and still more news to come over the next few weeks. Finally the market is waking up to this share DYOR

Currently top percentage gainer of the day that should make people notice us. It will be good to see the directors exercise their 6p options as that will really give a confidence boost. I suppose the market price would have to be around 7.5p to make it worth their while.

I suspect my lonely existence here will soon be at an end so welcome all.

you are not alone.............

No you are not alone, I have 3K of shares and am looking forward to a bit of profit.

Hi guys. What a day - a bit of a rollercoaster. Interesting that Paul Garrod should up his stake from 27.5 mill to 30 mill shares as per yesterdays release. We believe him to be one of the directors dentist so not a man they would want to upset when he has a drill in his hand.

We've been promised news on scale up and moa research in the 4th quarter as well as possible new research into MS & Parkinsons. Successful scale up should lead to the 28 day toxicity testing for a nutra product and then if you saw the Wall St interview Percy anticpates royalties on an estimated 100 mill a year sales so poss 10 mill a year to Regen- he says as early as next year. Then with a license in place he can move on with phase 3 for the Pharma product where he says he has had projected sales of 1-5 billion poss in 2007.

In the meantime there have been the rumours about a possible acquisition by Regen of another company as per the growth investor report a couple of days ago.

It is certainly an exciting share to be in at the moment and as for the long term one can but dream how high it may go.

RNS out today.

Yes - this is good news. The deal in itself looks good being a 250,000 purchase price for a company with at least 50,000 p.a profits. The real value however is in the strategic nature of the acquisition. The new company are involved in the gastro-intestinal area which fits in very well with other uses for Colostrum based products. It will very possibly fit in with the plans for a nutraceautical product in the near future.

Regen are now no longer just a one product company. There is still all the other anticipated news to come re scale up, licensing partner etc as well as the fact that the release gives the clear indication that this is only the first acquisition. It will take a little bit of time for the news to sink in with the market as it was not what had been expected however it is very good news and shows that Regen are very proactive and thinking on a wide scale. It will only be up from here.

Next week might be interesting when the consideration shares are admitted to the market. Based on an anticipated mid-market price of 3.25p on close of business this thursday, RGT will need to issue approx 7.7 million new shares. In theory, this should dilute the current sell price by (only) about 2.5%. Could be worth stocking up, but the question is when. Before or after the issue of the consideration shares?

It is an unusual situation for the next couple of days. Regen will be wanting the share price to rise whilst GCPUL will be hoping it falls so they get more shares.

I wonder if Regen are prohibited from releasing any more news that might influence the price as it would seem unfair if the deal is done and then before settlement date they release some further news which sends the price northwards and then GCPUL in effect lose out. To this end I wonder how long ago the deal was actually put together albeit only announced today. The rumour was out a few weeks ago so could explain the absence of other news - just a theory.

I think that the price seems cheap both in terms of return on investment and taking into account the strategic importance of bringing such a company under the Regen roof. It may well be that factored into the equation was the potential upturn of the share price in the near future which would mean that GCPUL had not been undersold.

Either way - come Friday they will be working in harness to our mutual benefit.

50,000 profit on 1,000,000 turnover does not seem that great and I therefore wonder whether there will be any cost saving in the takeover which will increase these profits.

"We and the management of GCPUL have significant plans to expand GCPUL as part of the ReGen Group. We continue to actively examine further revenue generating and
profitable businesses".

This statement implies that they have been working together or at least in discussion for a while. (Significant plans not being put together overnight). It further implies that it is the first of the acquisitions and if I recall they had previously referred to "seeking" but now they are "examining" further revenue generating etc. Just a turn of phrase perhaps but then again even though the interims mentioned the seeking of acquisitions we didn't really pick up on the comment at the time.

Exciting times ahead.

share price has droppd from significantly from early October. Would have thought new was positive? What is the next piece of news we can expect?

Having a boring day so i thought I'd analyse all of the news so far and see what we could expect in the futre.

Scientific/Development news.

Looking at the AGM/Prelim statements Sir Percy said they were working on various on going programmes.

From the last AGM statement..

"We now have ongoing science/development
programmes at the following":

* University of Texas Medical Branch, Galveston,
Texas, USA.
* Roswell Park Cancer Institute, Buffalo, NY, USA.
* Open University - UK.
* Proteome Sciences Plc - UK.
* St George's Hospital, London - UK.
* EiRx Therapeutics Plc - Ireland.

Looking at the interim results in September...

"In this regard we expect an in-vitro Study
evaluating the use of the compound in Parkinson's
Disease to start in the third quarter of the year."

"On 5 April a new method for the extraction of
ColostrininTM from colostrum was published in The
Protein Journal"...."We expect to issue a full report
on this during the fourth quarter of 2004".


Research Updates received so far.....

20/05/04 08:39 UKREG Research Update
In-vitro study - "Can prevent the aggregation of
beta amyloid"
In-vitro study - "Can block the proliferation and
promote the differentiation of primary cells into
neuronal cells"
Carried out by the University of Texas and Roswell
Park Cancer Institute

16/06/04 07:00 UKREG Research Update
In-vivo Study in Chicks - "ColostrininTM was shown
to have a very strong effect in enhancing memory"
Carried out by the Open University

22/07/04 07:01 UKREG Research Update
In-vitro Study - "Can prevent the aggregation of
beta-amyloid and prevent its toxic effect on cells"
Carried out by St Georges Hospital

Research Updates still to come

* EiRx Therapeutics Plc - Ireland.
* Proteome Sciences Plc - UK.
In-Vitro study Parkinson's Didease
Report - New method for the extraction of
ColostrininTM (due "Fourth quarter of 2004"

Commercial News.

Looking at past company statements it is interesting to see the progress regarding progress to a licensing deal.

12th Feb 2004

"..will place ReGen in a position to begin the next
stage of clinical development around the end of
2004"

".....working with a licensing company to assist with
finding such a partner"

17th March

"We believe that the publication of the article
communicates.... to a much wider audience,
including potential development and/or marketing
partners".

22nd March

"...may carry out research into the use of Colostrinin
for other medical treatments"

"..treatment of other diseases including: Multiple
Sclerosis,Parkinson's Disease and Amyotrophic
Lateral Sclerosis (Lou Gehrig's Disease)".

"...consider research into these areas at the
appropriate time, possibly in collaboration with a
development partner"

23rd March 2004 (from US Presentation)

"We assume development work.....is taken on by a
third party by the end 2004/1 QTR 2005"

20th April

"Our agent has identified a significant number of
potential partners... progress continues in this
area".

15th September

"...have established contact with a number of
potential partners ..discussions are ongoing"

"the more medical, scientific and commercial inputs
we have the better deal we can strike"


Or in a nut shell..

February............Want to start phase 3 at end of 2004,
looking for a partner to be able to do this.
22 March...........Will consider testing for Parkinsons at the
appropriate time with a possible partner.
23 March...........Want to start phase 3 at end of 2004.
We need a partner.
20th April...........Found lots of partners!
15th September..Talking to partners.
Waiting for more scientific/medical
/commercial inputs before we strike the
deal and announce Partner/start of phase 3.


Pretty consistant progress towards their goals at the end of
2004 ("ReGen will be a very different company at the end of the year"

So I think we are definately on course for news of a licensing partner by the end of 2004.


If you were to analyse the above in a speculative way then
a few things stand out.......

22nd March."Will consider testing for Parkinsons at the appropriate time with a possible partner"

15th September "In this regard we expect an in-vitro study
evaluating the use of the compound in Parkinson's Disease to
start in the third quarter of the year."

Which could raise some very speculative questions.

The appropriate time to start testing for Parkinson's was the last 2 weeks of September therefore have found a possible partner?

If they have a posible partner then a deal is on the table?
If you have a "better" deal then there must already be a deal to improve on?
The commercial input for a better deal was buying GCPUL?
The scientific/medical input for a better deal is the results of the Parkinson's study?

Pure speculation of course!

Anyway lots of news to come and IMO the big one being Parkinson's followed by a licensing deal. Probably in December depending on how long it takes to do the Parkinson's study. Anyone know?
I think the news will be released a bit at a time to maximise the PR opportunities.

Certainly 12p by xmas.

IMO DYOR etc. etc.

Ten Pints - excellent report,like the way you have put it together.I see you suffer from the same level of optomism and exhuberance as myself re:"certainly 12p by xmas"...and we sincerely hope you are right.I think it is always a problem with any scientific study to say how long test will take. How long will it take you to invent anything? answer is always as long as a piece of string!So i think the key is whether the product is good and meets the performance levels targeted. If it takes an extra month...well for 12p a share its perhaps worth the wait. Although this is where I have a problem in that unfortunately, patience is not my forte!

So we are back on track again. The recent NOIT sale of 3500000 shares has cast a shadow over trading with a number of people jumping ship in concern at a falling price and no explanation. Now we know there was nothing sinister to do with the company just NOIT needing to raise funds then normal service has resumed. Already up 9% today and people are still buying. I bet there are people kicking themselves that they didn't buy a couple of days ago but then IMHO there's a lot more in this one yet.

"Shares in Regen Therapeutics jumped 0.25p to 2.875p on talk that the company is set to announce some good product news. Speculation also mounted about a possible US fundraising. "

This appeared in various tipsheets yesterday so should attract some attention.

Hopefully they are correct and the good product news will be to do with successful scale up which will be one big step forward.

So everyone knows about the presentation and we have now news on the US. Further more comprehensive RNS coming out on Monday. Interesting few days ahead.

Strange the comment about no further financial information being discussed other than cashflow and estimated expenditure. I can only assume that is to allay the fears of those who were worried that it might be leading up to another issue/ cash call.

So Monday will see another RNS relating to

1. Drug development.
2. Nutraceutical development.
3. Conducting clinical trials.

That's what we want to know about. I think most of us knew that it would probably not be announcing a licensing partner however hopefully we will hear about scale up and toxicity testing as well as likely timescale for a nutraceutical on the shelves. Indications had been that we should see satisfactory scale up by the end of the year and perhaps a nutraceutical in 2005. Confirmation that they are still on target or fairly close should create a bit of positive activity.

Meantime the US. Put colostrum into any search engine and see where it takes you. 9 out of 10 times to the US. They seem to love any sort of colostrum product out there so this new exposure should spell good news.

Anyone know how this US arrangement will work? The RNS does not mention any new shares being issued so can we assume that any purchases will be coming straight from existing stock - if so that is great news.

This link which was kindly found by Dave on iii takes you to the adr info. http://www.adrbny.com/dr_profile.jsp?cusip=75885C105. Effective date today. Just asked Jeeves and it appears it is 4.58 in New York so can we assume there might be movement in about 3 hours?

If every one ADR equals 200 Regen shares then surely each time a purchase is made then the equivalent number of RGT shares will need to be purchased over here and held somewhere as security. If so then once trading starts we should see some fairly big movements. Every time someone buys 1000 ADRs it equates to 200000 rgt shares if my maths is correct. If I'm right in my thoughts above then we could see some fairly rapid movement.

Great run up to Christmas and roll on Monday

Found this on the web. It seems that the purchase of ADRS will create a parallel trade here for relevant number of RGT shares as no extra stock has been issued. I don't know how or when these trades will show up on our screens although we can track them through Daves link earlier. It will be nice to see the first trades in action over there later today.

Definition of American Depositary Share (ADS)

Convenient way to invest internationally
Listed and traded in the U.S.
Currency Risk

An American Depositary Share ("ADS") is a U.S. dollar denominated form of equity ownership in a non-U.S. company. It represents the foreign shares of the company held on deposit by a custodian bank in the companys home country and carries the corporate and economic rights of the foreign shares, subject to the terms specified on the ADR certificate.

An American Depositary Receipt ("ADR") is a physical certificate evidencing ownership in one or several ADSs. The terms ADR and ADS are often used interchangeably.

Convenient way to invest internationally

ADRs provide U.S. investors with a convenient way to invest in non-U.S. securities without having to worry about the complex details of cross-border transactions; they offer the same economic benefits enjoyed by the domestic shareholders of the non-U.S. company. ADRs are issued by a U.S. bank, such as J.P. Morgan, that functions as a depositary. Each ADR is backed by a specific number or fraction of shares in the non-U.S. company. The relationship between the number of ADRs and the number for foreign shares is typically referred to as the ADR ratio.

Listed and traded in the U.S.

ADRs can be listed on any of the U.S. exchanges, such as the New York Stock Exchange (NYSE) and the American Stock Exchange (AMEX), and may be quoted for trading on the National Association of Securities Dealers Automated Quotation System (Nasdaq), the NASD's over-the-counter market, or the pink sheets. They can also be privately placed and traded as Rule 144A securities. Finally, the concept of the ADR has been extended to other geographical markets, resulting in structures known as global depositary receipts (GDRs), international depositary receipts (IDRs), and European depositary receipts (EDRs), which are generally traded or listed in one or more international markets.

Currency risk

Although ADRs are U.S. dollar denominated securities and pay dividends in U.S. dollars, they do not eliminate the currency risk associated with an investment in a non-U.S. company

Thanks for the excellent research and information on the US deal, takes away a lot of the mystery. Here's looking to a great result early next week, and for future growth, all the best,
Steve

Anyone know why the recent decline? I thought things were bubbling and news was expected of further pogress in testing/research and in finding partners for the future?

Probably no real reason, there are always going to be those that get fed up with the lack of action and move on.

Anyone have any views on today's results announcement? Personally I think that the reduced losses, first sales and potential acquisition targets makes for encouraging reading. However, the SP has taken a bit of a beating.

q1- Yes the results look good but two days ago an institution sold 1 mill shares. Admittedly thats only 20,000 but why would a fund manager want to slide out just before some good results? Anyway the company is still telling a good story so I think I'll keep with them for the next year or so. There is every chance that the sp will be 4 or 5p by then. At todays price there is not much point in geting out

Realistic - if you check out the NOIT (the 1M sale) news you will see that they seem to be selling out holdings in various companies and yet not buying anything so probably can't read too much into their sale here.

Todays fall especially earlier I think purely resulted from frustrated holders selling out. There had been an anticipation that because the company had indicated that they would be making a preliminary statement in Feb prior to the results in March then there would be some good news possibly re scaleup or licensing partner. Unfortunately this was not the case and so a few bailed out which caused a drop and others therefore panicked and sold out as well taking it down further. Once the initial panic was over the price crept back on good buying levels this afternoon.

In reality things are really no different today to what they were yesterday. The price has been hampered by the Dec issue which has meant that Hoodless had a lot of stock to offload. Level 2 until today had shown that only they were on the 2.25 offer with 4 others on 2.75 so once that stock cleared the price was set to rise. Ironically the drop today has created more buys than sells so some more the issue has gone aiding our cause.

Another frustration has been the ADRs. The announcement was made back in Dec that the process had been set up and gave the impression that trading was starting in the US then. In fact although the ADR process had been set up the brokers still had further paperwork to do to be able to trade and as I understand it they are just sorting the final details with NASDAQ now which is why as yet we have not been advised who the US brokers will be. I am sure there will be significant buying in the US when trading does start as colostrum is already a recognised health product out there. The fact that the Bank of New York need the shares lodged with them to create the ADRs on a 200:1 ratio means that applications for ADRs will have a direct impact on the UK stock and will hopefully clear the last of the issue and move the price up.

The results show encouraging figures. the GCPUL income was based on just a few weeks and so should equate to around 500,000 next year on a like for like basis. The cash in the bank and debtors total approaching 2million. So with a likely expenditure of around 1.5 million next year they have enough funds for the year already and a million left over. As a result I am puzzled as to why they needed to issue so many shares in Dec. It would seem, based on what we've been told so far that they don't need all that money "now". If they do then we have more to hear perhaps on the acquistion front.

There were many references to "broadening the base" of the company in the results and I think this is perhaps to address the concerns of those who have worried about Regen being a one product company. It's great to have a larger companybut I hope they don't lose sight of the reason most of us are here which is to see a Colostrinin product on the shelves -that is where the real money lies.

So we still wait for news on Scale up, the actual start to ADR trading, the finalising of a licensing partnership and any other acquisitions. All of these will see the SP lifted from this low level and hopefully such news won't be too far away.

Sorry a bit of an epic but I haven't posted here for a while. Good luck to all holders.

Gantenbrink - Excellent post and well worth the effort - Many thanks.

Thanks q1.I had hoped that the ADRs would have been trading by now.Good post,perhaps post of the week! I'll print it out to sustain me on the bad days when there are few trades.I'm glad that I did'nt panic now.

Gatenbrink- Sorry all the credit is down to you,only noticed when I went back and re read your post.

And I was going to take all of the glory...!

Thanks for your kind comments.

Interesting that one of the trades this morning was an MM buy at 2.1. Why would they be buying now?

Anyone still in on this one?? I had a look last August and stayed out at the time. Interesting applications for the product but cash and one product kept me away. Is this any closer to take-off? What are the upsides and downsides from here of RGT?

Andy
I have some tucked away. Just watching and waiting. Could be anything

Me too jeffmack. Very small holding that wouldn't be a disaster if I lost it all but would be most pleasant if it were to take off...

This is better...

LONDON (AFX) - Drug development group ReGen Therapeutics PLC said it will begin to research a treatment for Parkinson's disease, after its Alzheimer's drug Colostrinin was found to protect cells that are depleted by the brain degenerative disease.

In a statement released to coincide with the group's annual shareholder meeting, Professor Peter Jenner, the chief scientific officer of Proximagen Neuroscience PLC that conducted the study on ReGen's behalf said he recommended Colostrinin be evaluated for use with Parkinson's disease sufferers.

Chairman and chief executive Percy Lomax said: 'This is a very encouraging finding. We believe that not only does it confirm the general neuroprotective effect of Colostrinin that we are now developing as a nutraceutical, but it shows that a second peptide, naturally present in this complex, has activity in its own right.'

Separately, he said the company is in talks with a number of potential licensing partners. 'The company continues to believe that a partnering deal in nutraceuticals is possible in 2005, with revenue from sales in 2006 and a partnering deal in pharmaceuticals in 2007.

ReGen added it is 'firmly focused on developing its revenue-producing business'. It is pursuing a number of opportunities in this area, and sees the contract research area as a potential path for expansion.

So a positive day on the markets. Hopefully the start of an upward trend.

You will have seen all that happened at the AGM from the different releases during the day. Did anyone else get there from here? There were a few faces I hadnt seen before but most had gone soon after the end so I never got the chance to meet them.

The meeting started with PL asking if anyone had any questions. I obliged again and again and again hence it lasted an hour and a half rather than 1/2 hour. On this point though I know a number of people have criticised PL but there can't be many chairmen who would answer as many questions as people can ask at an AGM and I stand by previous comments that he comes across as both genuine and acting in our best interests.

Moving on the key facts for me were:-

The studies re Parkinsons now mean that they have at least one more string to the bow. The fact that they have a synthetic peptide that seems to work means that by virtue of it being synthetic they can readily make it and potentially this could be licensed out at an early stage to generate royalties in the same way as a treatment for Alzheimers. So there could be 2 different revenue streams. We wait to see if the research shows up any other areas which it might also help. No doubt the more scientific amongst us can comment further on the scientific value of the findings/ progress so far

There was a lot of emphasis on the comments in the statement regarding a deal within 2005 for the nutra with sales next year. There was also mention that this might not necessarily involve the partner/s doing the manufacturing. I got the impression that we could be looking at different partners for different regions and in some cases this could involve Regen doing the manufacturing. Whatever the situation my personal take was that we should have at least one of these deals signed up before the end of the year. If there are to be sales in 2006 ( and this was mentioned a few times) then they will need to have the deal done, material being produced, supply lines established and marketing taking place so I cant see that it can be too late in 2005 for the deal ( but that is purely IMHO). I know that Runtus has done the figures on potential nutra sales before but this could be key info soon if for instance the first deal is for the U.S. as if we get say 5% royalties of say $50 100 mill sales then an income of 1.5 - 3 million a year would put a rather different perspective on the share price.

I queried news re scale up and very much got the impression that this will go hand in hand with news of the first license deal why I dont know. I pushed the point but didnt get anywhere. Id be interested to know if anyone else was there how they interpreted this point.

ADRs apparently can be bought but Regen were not expecting any activity as yet as they felt it would take a while before they got going. Seemingly they were available from a couple of weeks ago although I will follow up a contact that I got for Pali and see whats happening over the next week or so. (Apparently when British Land launched their program it took a year to get going and they are a higher profile company)

GCPUL is still planned for large expansion. Again nothing specific on this but I got the impression it wont be long before we hear more in this area. I seem to recall that at present it is generating about 500,000 p.a for Regen so expanded this might go some way towards the current cash burn of 1.5mill p.a for the group.

Resolution 9. This was an area I was concerned about as it seemed to indicate we would pay if a director messed up. When I queried, it would seem that the company would pay to defend an action if it was brought against a director but if the director was found guilty they would have to repay the company and on this basis I went along with it.

I specifically asked if there was any intention to issue more shares in the immediate future as I had been upset that last we met that no mention had been made of the issue that was to take place the next day. I was assured that there were no imminent plans. Mention was made that they were budgeted up to the end of 2006 albeit in a separate discussion to my issue question so I dont know whether a further issue is factored into their budget over the next 18 months.

All of the above as you will appreciate is purely my own impressions of the meeting and information that was publicly discussed relayed in good faith. I know last time another holder who attended had a slightly different take on some areas which is always useful so if there was anyone else there I would welcome your thoughts.

All in all quite a positive day. The share price has risen some 28% on what is essentially still a small volume of trades which perhaps signifies that there is not too much liquidity in the stock so hopefully a bit more buying will continue the upward movement. I did comment on the fact that I would like to see the Directors buying a bit more stock as a display of their confidence. That I am sure would bring a significant uplift. I appreciate they have to be careful about inside info etc but there must be a point where they can buy and after an AGM would seem as good a time as any we shall see.

Meantime we wait to see if the press pick up on it at all. as a prelim tonights Stockmarket Reporter said:-

"Shares in ReGen Therapeutics jumped 0.42p to 1.92p after the company said that it was now committing resources to Parkinson's disease research after a positive study of its Colostrinin compound. Colostrinin and a synthetic homolog of Colostrinin-derived peptide showed neuroprotection in a cell line model of Parkinson's disease, it said. The company also said that it was engaged in a number of ongoing negotiations with potential licensing partners."

Let's hope tomorrow sees a continuation of todays positive rise.

Gantenbrink
Thanks for the write up

Gantenbrink

Echo that sentiment. Thanks for the review. Things are sounding positive and on the up. Have to think about increasing my holding.:-)

check out the 'iii' web site bulletin board

never have so many for so long had so much positive stuff to say about a share that has spent so long going NOWHERE................fast

why do the pharma share BB's attract so many experts?
all comments are laden with techy stuff....

but the share still goes nowhere (on a good day.....mostly it goes SOUTH)

A 15% rise today which was very well needed after such a poor run. Perhaps a corner has been turned...

Mr Garrod has bought another 1,000,000 shares taking his holdings to 11.3%.
Obviously must feel pretty confident, think I will hold onto mine as well.
Forgot to add he is a Non Executive Director.

That's only 15k but is still an indicator that all is not lost.

Header updated with news of scale up and some quotes from the Wall Street Interview which is to be published today:-

http://www.twst.com/notes/articles/abz622.html

Hopefully solid progress and a rising SP from now on.

In the words of chairman Percy Lomax today

"You have a real company as opposed to a hope company"

Real profits and real sp movement northwards is now the order of the day!

I'll drink to that.

Little by little we're getting there. The last 2 weeks must have seen around a 60% rise.

I have to say I had never imagined that the Share Price would be as low as this once scale up had been announced but I think it's because it took slightly longer than they had expected.

Confidence is beginning to return and newsflow is improving so hopefully we will see the rise continue to a realistic level. Then drop in news of a licensing partner and we're away

Gantenbrink - what do you feel is a realistic level for RGT as this time?

I bought quite a number of shares at between 3 and 4p when they were not as advanced as they are now. There has however been some dilution since but I would still have expected that they would, with news of scale up and GCPUL revenue, be more towards 5p. Licensing partner, tox tests and GMP will mean that sales are just round the corner and a much higher price

An interview a while ago (not yesterdays) with Percy Lomax hinted at 5% royalties of estimated sales of a nutra of 100 million a year so 5 million a year to Regen.

That's aside from GCPUL, the vetinary angle, the other nutra (as per yesterdays interview) further expansion and the longer term and almost incomprehensible income that would come from either of the two pharma products - AD at royalties on an estimated at 1-5 billion in sales & Parkinsons - where I haven't seen figures ( naturally if they are successful through testing etc - but so far no side effects shown which is a key attribute)

Currently the market cap of the whole company is only around 7 million. For the reasons above I remain sure that this SP has a long way to go.

Thanks for that and interesting thoughts. If you're right, the company is currently very undervalued - ripe for a takeover perhaps or are the products not sufficiently advanced to tempt a potential suitor?

Now that the new facilities are available on these threads I have stuck a picture at the top for a bit of fun. The fuse has been lit I just wish they'd take off.

Takeover? I hope not. We've come this far lets' hope they finish the job. It is a worry though with such a low market cap. I wonder what level they could reasonable defend. 10p/20p. To a large company this wouldn't be a huge expense.

It is a bit of a vulnerable stage with the SP being so low but I think most of the major holders are in for the long term. On another board an attempt at a straw poll based on 6p & 10P highlighted the fact that no long term holders would even give such prices the time of day.

As I say we're so close now to the first product sales it will be nice to see it through and realise the gains we've all been waiting on.

Finally Hood have moved up on that offer (From 1.75 to 1.85). They have been adrift of the pack for a while with the others at 2.00/ 2.10 and three at 2.15. They obviously had some cheap stock to clear so hopefully they have exhausted it.

Online buy limit has dropped to 75k whilst you can sell 375K at 1.7 so signs are good for a further rise.

Suggestions of 12p look way off now, - so do any of you that follow Regen have further news to support a recovery?
I suspect the cash-position is the killer, as it was for Xenova - things always take longer than anticipated.
Running out of cash is no excuse, but it's usually fatal.
I don't follow the co. - so a resume would be useful as a starting point. Thanks.

Suggestions of 12p look way off now, - so do any of you that follow Regen have further news to support a recovery?
I suspect the cash-position is the killer, as it was for Xenova - things always take longer than anticipated.
Running out of cash is no excuse, but it's usually fatal.
I don't follow the co. - so a resume would be useful as a starting point. Thanks.

hangon - I have tried to keep the header updated so most info is on there. Suggestions of any price can purely be conjecture until the hard facts of a licensing deal are seen but many people would feel that if there is a half decent deal which generates the sort of royalties the chairman has alluded to in the past then the price would be significantly above where it is now.

We have seen a bit of activity today and I can find no real hard facts as to why. There does seem to have been a bit of smoke around but no fire with people saying they've heard news of a deal etc. When we know for certain then we will see the real rise but I am sure most people don't want to base anything on what someone heard from their best friends cousin who was sitting behind a guy in a pub etc.

You're right about the cash. I haven't got figures to hand but I did take a thorough look at the accounts for last year along with projected cash burn for this one a few weeks back and in my estimation they need to get fees in for a licensing deal before the end of the year to avoid having to do an issue to cover ongoing costs. There are a few variables which it is difficult to quantify such as how much profit is GCPL making and are there any savings now they have achieved scale up. If they go much past the interims without a deal then I suspect they will start getting financially twitchy about wanting to get a bit of money in the kitty for reserves but that's just IMHO.

The interims are about 6 weeks away so we will at the latest know more then. Beyond that it's a gamble. Indications are that they are very close to a deal as they were discussing terms a few weeks back but until the pen's are on the paper it could be tomorrow and it could be never. The chairman seems confident of sales in 2006 and there is a lot of legwork between achieving scale up and getting sales one of the first steps of which is a licensing deal so he must feel it's close.

Hope that's of some use and please if anyone knows anything more definite about the rumours doing the rounds today do let us know.

Thought it might be of interest that news of Regen is beginning to spread. Up to now their PR has not been great but even so word is getting out worldwide. We know there have been various articles in the States but 2 recent articles have appeared as news in India and Australia.

India 29 July Specific reference to the work of Regen

http://www.medindia.net/News/View_news_main.asp?t=gn&x=4154

Australia 19 July No reference to Regen but focus on their patented product Colostrinin

http://www.abc.net.au/rural/content/2005/s1417588.htm

Credit for finding this info goes to a poster elsewhere (McGraw) but Im sure he would happy for it to be posted here as he doesnt post here himself.

Superb research on share trading in Rgt by a poster elsewhere seems to show overhang all but cleared which could explain the price starting to slowly move.

I got the okay to post the link as he has put it on a web site.

As I say this is all the hard work of The Ford Prefect - I am just the messenger.

http://www.ohmica.co.uk/rgt/rgttrading.htm

Up 40% today. Well done to all who still hold. RGT could now be going places!

ReGen Therapeutics announces grant of U.S. patent on use of Colostrinin(tm) to
promote induction of Cytokines

ReGen Therapeutics Plc ('ReGen' or the 'Company'), a company whose product
Colostrinin(tm) has shown efficacy as a potential treatment for Alzheimer's
disease, announces that a patent on the use of Colostrinin(tm) as an inducer of
cytokines has been granted by the United States Patent and Trademark Office. The
patent is owned by the Board of Regents of the University of Texas System and is
based upon long term research at the University of Texas Medical Branch (UTMB)
at Galveston, which has been sponsored by ReGen. UTMB has licensed the patented
technology to ReGen under the world wide exclusive license agreement that exists
between the two parties.

The new patent covers the use of Colostrinin(tm), its constituent peptides and
analogues to promote cytokine induction. Cytokines are molecules that are
involved in communication between cells.

Potential utility of this patent is expected to be welcomed by people with
Alzheimer's disease, because 'the induction of cytokines can modulate the immune
response in those patients' said Dr. Kruzel, Scientific Consultant to ReGen and
Adjunct Professor at the UT Medical School at Houston.* He also added that the
present invention provides a method of modulating an intracellular signalling
that leads to reduction of cell damaging reactive oxygen species (ROS). Both are
important in the context of Alzheimer's disease and may go some way to explain
the clinical benefits shown to be associated with ColostrininTM in clinical
studies'.

The grant of this patent adds further strength to the intellectual property
portfolio owned by or licensed to ReGen. ReGen now holds rights to 5 different
patents relating to Colostrinin(tm); one for the use of Colostrinin(tm) in
Alzheimer's disease and other neurodegenerative conditions (granted in 10
countries), one for its use as a dietary supplement in combination with other
substances (granted in UK) and 3 UTMB 'mode of use' patents (granted in USA).
The Company has filed a number of other patent applications in relation to
Colostrinin(tm) its constituent peptides and analogues and these are currently
being evaluated by the relevant patent authorities.

Commenting on the latest patent grant, Chairman Percy Lomax said 'This is now
the third granted US patent to come from our long standing association with UTMB
and represents further progress in our development programme. It remains a
pleasure to collaborate with such an excellent team of scientists.'

Hi queen1 - our patience is being rewarded and this is really only the beginning. The fact that this is a patent in the US is also a good precursor to the fact that the most likely first nutra license will be N.America. The activity today shows how many people watch Regen so where will the SP go when the first license is announced?

I suspect we may also get some press coverage which can only help.

It will be interesting to see whether this causes any movement on the ADR front for once the US starts buying the shares as well we could really move forward.

I think all those who hold will be pleased to have their shares safely tucked away for it just shows how quickly things can move and it could well be very difficult and expensive to try and get them on news of the first license which based on company info could well be any time.

Exciting times ahead.

Exciting times indeed Gantenbrink. The sp has just about recovered to where I originally got in which helps.

A superb link here to an evaluation of Colostrinin. Research data etc. I know some people are passing this on to the media as it could bring hope to AD sufferers that progress is being made and that all indications so far are that Colostrinin is safe ( no particular side effects)

http://66.102.9.104/search?q=cache:rNXipWgU2Q4J:www.biomedcentral.com/content/pdf/cd-581670.pdf+colostrinin+&hl=en
--------------------------------------------------------------------------------

Acquisition of Rights

RNS Number:8809Q
ReGen Therapeutics PLC
06 September 2005


ReGen Acquires Rights To New Use for Well Known Drug

6th September 2005

ReGen Therapeutics Plc ('ReGen' or 'the Company') announces that it has entered
into an exclusive option arrangement with Sciencom a private company, which has
discovered an important new use for zolpidem, a long-established drug, currently
marketed for the treatment of insomnia. A patent application has been filed to
cover this new use.

A significant body of 'open' clinical case observations has shown that zolpidem
can normalise areas of brain dormancy secondary to a primary lesion in brain
damage conditions e.g. stroke, traumatic brain injury, vascular dementia and
Bell's palsy. The clinical effects of this dormancy reversal have been
restoration of consciousness, swallowing, co-ordination and motor function after
stroke and traumatic brain injury. Given that stroke alone is the largest single
cause of severe disability in England and Wales, with over 250,000 people being
affected at any one time, the Company believes that this represents a
significant medical and commercial opportunity.

This reversal of dormancy has been visualised by SPECT brain scanning on dosing
with zolpidem. The clinical effect is generally proportional to the size and
position of the dormant area and correlates with drug levels in the brain/
plasma. Whilst to date these effects have been achieved with existing
formulations these are less than ideal for the new use, with sedation as a
significant limiting factor. ReGen is therefore looking to develop new
formulations to optimise the delivery of this important clinical benefit to a
diverse range of patients.

With this in mind, ReGen is managing a feasibility study. Assuming the success
of this study ReGen will undertake several studies, in collaboration with its
recently acquired subsidiary Guildford Clinical Pharmacology Unit Ltd, designed
to demonstrate clinical proof of principle. Positive results in these studies
will trigger a shares only option payment to Sciencom and the results will be
used to find a commercial partner to complete formulation, clinical development
and marketing.

Commenting, Percy Lomax, Regen Chairman and Chief Executive said 'We are pleased
to announce the acquisition of rights to this project, consistent with our
previously stated intention of building our business to both diversify risk and
increase value for our shareholders. Our estimates suggest that the total
potential world market is around $5bn per annum. It is important to note that
this project could be in clinical trials very early next year.'

For more information, please contact:

Andrew Marshall
Marshall Robinson Roe
Tel No 020 7960 6007



This information is provided by RNS
The company news service from the London Stock Exchange

END

In the past people have been concerned about Regen being a one product company but things have now changed.

This product could be in clinincal trials early next year and has massive potential

The indications are that the AD and Parkinsons products will be in clinical trials in 2007.

The nutra version of Colostrinin is expected to be on the shelves next year.

Meantime the strategic importance of the GCPUL acquisition has been demonstrated by virtue of keeping research costs in the group. I also wonder whether it gives Regen access to breakthroughs with other drugs and the chance to get involved at an early stage. e.g. was todays association anything to do with a contact through them?

Interims are due this month and there is quite a bit for us to be updated upon including the first real glimpse of income that is coming from GCPUL.

The nature of the likely treatments uses for this drug ought to see Regen getting some media coverage as well which could also have a knock on effect of interest in Colostrinin.

Gatenbrink - again, good news but all of the gains from the recent fantastic announcement have been given up over the last couple of weeks. What's it going to take to actually get these motoring and to stay motoring?

queen1 - your guess is as good as mine. How much positive news can they release before it goes up and keeps going....?

No idea....but it's dropping again today :-(

why are they going up today?

The mm's started to move the price up first thing and continued through the morning. All told 5 of the 6 mm's moved up today. I think two of them increased twice.

There is a city presentation now on the website. This took place last week and seems to have targetted institutions. There was nothing major within it hence no RNS. The interesting bit seems to focus around Zolpidem about which the presentation reads fairly positively and in the summary states that they will be going to trials in 2006 so they seem to have moved on beyond the feasibility study.

If you haven't seen it have a look at the Regen website. There was nothing about the nutra partner which we are all waiting to hear on. The year has seen them getting progressively more positive about a deal from looking for, to serious negotiations to discussing terms but so far we have not heard about someone taking a pen out of their pocket and signing. N. America looks like it should be first but it would just be nice to see it agreed.

Two late 500,000 buys bode well for tomorrow. Fingers crossed there is some positive news on the way.

It would be good to get the positive news before Xmas!

I have seen a very positive broker note from Regens brokers JM Finn & Co. I got it yesterday and it indicates that " Zolpidem project gets green light". Apparently they are going to exercise their option to acquire for a "modest sum payable in shares". It goes on to say "Regen is gearing up for a phase 2a clinical trial of a low dose formulation of Zolpidem in early 2006" and then "we believe Regen will not have difficulty in finding a partner". IMHO Zolpidem looks a very exciting drug and the fact that it has already been used as a drug for other uses is probably why it can jump straight to this stage of trials.

On Colostrinin nutra it says "Management remains confident that a partnership for Colostrinin can be concluded in early 2006 allowing a product to be launched, at least in the US, as early as Q4 2006". It also says the vetinary version should go to trials in early 2006.

On valuation It says Regen has a current enterprise value of around 4 million. "We believe even a very cautious projection of sales of Colostrinin would support an enterprise value of around 30 million. This valuation assumes no contribution from the pharmaceutical programmes which should have even greater potential in the longer term, especially given the Zolpidem project"

All very reassuring and might explain why we are beginning to see a bit of life. No doubt there should be an RNS coming out when they actually exercise the Zolpidem option which should attract some attention and will mean that Regen will no longer be a one product company which I think has been a concern to some in the past.

Good luck to all

Thank you for the information Gatenbrink, all very positive !!

RGT is continuing to do well this week. Impending news?

Price is moving. Volume picking up. Various bits of news anticipated which could send us well north of here.

A partner for the Colostrinin nutra? News on Zolpidem - exercising of the option, entering trials with a partner and a hefty signing on fee? Either of those would be fantastic news.

There is definitely a positive air around Regen at the moment judging by various boards so hopefully our patience is soon to be rewarded.

I hope so Gantenbrink. I got in at 2.30p so still some way to go to break-even on this one. But I still believe it will come good...

queen1 - I bought loads in the 3 to 4p range but managed to drop my average to just below 2p when the price fell as like you I felt sure that this would come good in time. If a certains poster on advfn is correct then we have no worries as it will be 28p by May. I wait to see - although in his defence he has predicted a number of recent events with surprising accuracy.

28p by May? And what does he base that on?!!

Well there is your news.not quite as exciting as i thought . we bought sceincom .should have averaged .

queen-- a consolidation I expect. This is ashare with a nominal value of 0.1p, so it wouldn't do any harm to make it a 10p share. But that wouldn't be much good for us would it?

Not really. Still, there seems to be an air of optimism around these last few weeks so perhaps we will be pleasantly surprised...

Who knows where that chap gets his info but I wouldn't rush out and buy on the back of it though. Saying that he has predicted the last two RNS with surprising accuracy as well as changes in online trading limits.

Putting that aside it is good to have another product on the go at Regen and also one that is going to jump straight into phase 2. Zolpidem is already an established drug on the market for another use so that must tick quite a few boxes in respect of forthcoming trials for issues such as side effects etc.

GCPL are to undertake the phase 2 trial. This explains the logic for their acquisition for when opportunities such as this come along it means that rather than having to pay a 3rd party all of the research money stays inside the group.

The trials are to be carried out in South Africa which is where the initial positive effects were noticed when prescribing the original Zolpidem to stroke victims with insomnia. As a result there is already a knowledge of it there and you will note the wording in the release:-

"In this study we will be comparing a novel formulation with a standard marketed formulation in known zolpidem responders.' "

and

"A significant body of 'open' clinical case observations has shown that zolpidem can normalise areas of brain dormancy secondary to a primary lesion in brain damage conditions e.g. stroke, traumatic brain injury, vascular dementia and Bell's palsy"

So they already know that it works to an extent and have a certain amount of data available before going to trial. The fact that they are referring to known Zolpidem responders indicates to me that they possibly already have at least some of the volunteers who will be required for the study so we could see fairly swift movement.

"The clinical effects of this dormancy reversal have been restoration of consciousness, swallowing, co-ordination and motor function after stroke and traumatic brain injury" - This line from the release makes a pretty powerful statement.

It's a pity they didn't head up the release with something a little more exciting. "Regen to acquire Sciencom" - result - who are Sciencom? "Regen to acquire rights for potentially blockbusting drug which could bring relief to stroke victims" that would I feel have had a much more positive effect.

All in all a pretty positive outlook though and meantime we still await news on the CLN nutra licensing partner which they have indicated a number of time should be in early 2006 with sales in Q4 2006.

Shame the price has dropped back a bit today but I guess it's a case of buy on rumour sell on news so there were always going to be profit takers but for long termers the prospects seem a lot better now IMHO.

Thanks for that, much appreciated.

What do we think of the results chap? Steady as she goes?

Sorry queen - delayed reaction here.

I think there was a little disappointment at the lack of news of a deal. Elsewhere someone had been giving very definite info that something had been happening and it would be announced with the results and I suspect a few people jumped ship when it did not materialise. Personally I think the person in question was posting in good faith and did seem to know something of the activity within Regen as they accurately predicted 2 pieces of news in a given period with a 6 day interval some weeks before it actually materialised with the Sciencom deal.

Personally I would have been surprised to see them lump any news in with the results for it is much better to have a separate release for maximum impact.

In reality nothing has particularly changed from a couple of weeks ago. The nutra deal seems to have been in discussion for some period of time with the N. American partners and I personally wonder whether there is some tie in with the GMP. Purely my own conjecture but I wonder whether announcement of successful GMP may trigger a deal. From all they've said it should be fairly shortly. Certainly I hope so as I can't see that funding can last much longer without another issue unless they get some sort of deal soon, and nutra seems the most likely.

Hi Gantenbrink. Thanks, as ever, for your thoughts. The sp has been up & down a lot these last couple of weeks and news is definately required to give it some direction (hopefully positive). I still feel that there's a lot of potential here so happy to hold.

OK Peeps. What do you think " Due Course " means.3 months 3years ??. i'm wondering about averaging

I feel that's all quite positive. My holding isn't large enough to worry about averaging so it's either boom or bust for me, hopefully the former.

drug news looks promising.

From Sunday Telegraph (www.telegraph.co.uk/news) search under ReGen for this article:-

'Hello mum. Am I in hospital?'
By Olga Craig
(Filed: 28/05/2006)

It is copyrighted so I cannot post it here. Worth a read for anyone who has not seen it. It expands ReGen's RNS of 22 May a bit, also mentions ReGen's trials with Zolpidem.
kim

Hi all

Huge PR coverage of Zolpidem over the weekend including the whole of page 3 of the Times on Saturday.

Nature: 23 May 2006

http://www.nature.com/news/2006/060522/full/060522-9.html

The Guardian: 23 May 2006

http://browse.guardian.co.uk/search?search=zolpidem

The Times: 27 May 2006

http://www.timesonline.co.uk/article/0,,2-2199122.html

Sunday Telegraph: 28 May 2006

http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2006/05/28/npvs28.xml

Finally Regen get their PR together - could be a promising week ahead.

SP back down again, even after so much positive information about Zolpidem. I have to say that I'm struggling to understand the market's reaction to RGT.

What's it going to take to make these take off? Anyone?

Queen1, patience is required if you are going to reap the fruits of this little beauty! They are not far away from a breakthrough and a deal of some sort is also in the offing, though I am not sure how lucrative it will be but, as with any share of this type, a helping hand is needed and a bigger named pharma taking an interest will inevitably put a rocket under the share price. A year in a company like this is equivalent to a week in a company like, say, GlaxoSmithkline, if you get my meaning. A few years ago I would have said "good luck with your investment" now, I genuinely believe that luck no longer plays a part; they are on to something big. But as always, DYOR!!
kim

Hi Kim

Thanks for that. I've been a holder for 18 months now so I must have at least a modicum of patience!

Well done Queen1! I am sure your patience will be rewarded....in time!
kim

In the Daily Express today:

"Share Whisper

Shares in ReGen Therapeutics climbed 0.05p to 1.2p on suggestions the company was close to announcing a tie-up with a major US company.
Traders are also hoping for a positive update later this year with a clinical study in South Africa on a new use for its insomnia treatment zolpidem."

Thanks Dinky1, it will be good to see ReGen move into the big time, it is long overdue.
kim

Completely agree.
I don't usually post here, so sorry for intruding.
I am a long term holder who tends to post elsewhere....but I believe that Gantenbrink is away, so I thought i'd pop over here and post the news.
Good luck everyone! Hopefully our patience will soon be rewarded.

Not taken as an intrusion Dinky1, good to see you here, it is a much quiter thread than the other, perhaps we should have CB here for a while!!
kim

Response to press comment

RNS Number:6210F
ReGen Therapeutics PLC
04 July 2006

For immediate release

ReGen Therapeutics Plc

4 July 2006

Statement in response to press comment

ReGen Therapeutics Plc ("ReGen") announces that in the light of recent press
comment it is in discussions regarding a licensing agreement for the commercialization of ColostrininTM in North America. These discussions have been
in progress for some time.

A further announcement will be made when appropriate.

Another "buy on rumour, sell on fact" rise.

Possibly Keaydian, but I think that the sp is more likely to hold should the license agreement prove positive, also they have a very good chance of making the big time in a spectacular fashion if the zolpidem drug is marketed as one that can reverse severe brain damage. The results from studies so far are incredible.
kim

Hi guys. Thanks for posting the info Dinky1. I do not visit here as often as I ought, considering I started the thread but I tend to get caught up across the way so by all means post any news as it's good to see contribution and general activity here.

Anyway nice to see our patience being rewarded and Regen finally starting to be recognised.

Other news is that a Regen interview will apparently appear on ABC's Good Morning America tomorrow between 7 - 9am focussing on Zolpidem. It will be interesting to see how the US reacts. The markets have been closed there today. Tomorrow they'll hear about what the UK press described a s a "miracle" drug just a couple of weeks ago. Then on investigation they'll find that Regen are rumoured to be doing a deal on another product with a large company in their own country and then they'll see a share price that appears to be lifting off. If Pali Capital can get their act together and start shifting those ADRs (which equate to 200 UK shares) then US buyng could have a significant effect on our market.

Hopefully this is just the beginning. News of a deal should move us up further and then with Zolpidem and CLN pharma following behind the sky's the limit.

Good luck all

Welcome back Gantenbrink. With Discovery now in orbit and ReGen rocketing, it may be time for celebration?!
kim

Interesting times indeed chaps. Onwards and upwards!

This share is so frustrating! Down again and for no reason!!!

i take it everything we read on ADVFN is to be taken with a pinch of salt?? from being hugely bullish they have IMO turned somewhat bearish. I am not selling this till at least 5p where i will re assess the situation.

License agreement announced today with US neutraceutical developer, Metagenics, to commercialise Colostrinin.

good time to top up. low spread, good news, multibagger very soon .

More good news. CLN has Anti cancer and anti ageing properties. Should be a whole host of news to come with start of Zolpidem phase 2 trials, results of tox and GMP whilst all the time we draw closer to actual nutra sales via Metagenics. Need to see any overhang cleared from the issues and then we can see the positive effect of this news as it comes. Have a good long weekend everyone.

up again this morning

Still chugging along then!

ReGen Therapeutics says first-half sales figures are 55,000, reflecting what the company called 'the start of a healthy upturn in business.'

Turnover for the first two months of the second half of the year was 159,000, and the directors said that the current external pipeline looking forward is around 750,000.

The company said it now has over 1.2m of cash in the bank, taking into account its placing in July, which raised 1.1m gross.

Hi all

Just got back from the EGM. Great shame there were such a few shareholders there as we got the chance to ask questions for around an hour. I think there were only about 5 or 6 holders and as far as Im aware only myself and Asmodeus from the boards. Peter Garrod wasnt there nor was Tim Shilton. Tim is doing the rounds of Sterling, Metagenics etc. Most other Directors were there and also Malcolm Beveridge who some may recall resigned as a Director a while back for personal reasons but it seems is still holding his shares which I found encouraging

So I will attempt to address things in turn.

Firstly there was great disappointment that I had not logged onto the Regen website this morning for after all my moaning at them they have now updated it. I cant see any other reference here to the new look so it seems no one else has noticed but it is much more informative on the home page now which will be a great help to new investors doing their research so well done to Martin Small.

Nutra.

The good news is that it is still on target for sales in the US in H1 2007. The other good news is that it would seem that the reason we have not seen financial details and will not see them is because Metagenics are a private company and the intimation was that the deal is a good one so would not be in Metagenics interest to publicise it. When talking to the room about Zolpidem, PL was giving an example of figures and saying that even if the Regen percentage were as low as say 5% etc etc and then went on to say that the nutra deal was significantly higher so it would seem that the Finn indication of 10%+ is probably correct. I also clarified the fact that the manufacturing cut would be payable at the start, basically cash on delivery. Royalties I assume would however result from actual sales.

After much badgering it became apparent that tox tests & GMP only actually started about a month ago. Regen had apparently submitted all they needed but the hold up was in the US so there has not been a hiccup with the tests just that they started later than envisaged but this will not hold anything up. They still envisage no problems in this area.

Questioning about the Express article the other day PL said that they were in talks with a number of possible European partners, most of which were talking in terms of food supplements. It gave the impression that we could see different types of deal, one in this food additive respect and one more in the tablet form like Metagenics. He pointed out that it can take a while from a contract being on the table to it actually being signed as was the case with Metagenics. It would not surprise me if they were around the sort of table stage with at least one possible partner based on his use of this analogy.

Zolpidem

Trials will start in November. They have now got a contract for a documentary with a TV company and this will start filming in November and will be shown on Discovery Channel next year. This PL feels will be great timing as it is envisaged that results from the trials will be out in Q1 next year as well. They are confident that the trials will be successful as they are to be on known Zolpidem responders. The key aspect of the trials are whether they can reduce the sedation effect.

They have various agreements in place in terms of the delivery system (spray) etc and the market estimate is based on $1 a day for treatment. They fully expect to be able to license this out to a larger company at an early stage and seem happy enough about the patent situation.

CLN Pharma.

I get the impression we are barking up the wrong tree thinking about imminent deals here. They are indeed progressing with work on the petides and one has been successful in respect of Parkinsons but the indication was that we would not hear more in this area until next year as they push on to identify others.

Money

It was again reiterated that they do not intend to do an issue at the present time. When reading out the resolutions PL seemed to hesitate after saying pursuant to any fundraising just before saying and/ or business acquisitions. It has to be said that I was perhaps listening attentively at this point so perhaps his hesitation was more apparent to me.

I did take the opportunity to seek clarification as to why we were sitting at an EGM granting authority to possibly issue shares if they were not looking to raise funds and whether this meant that they were currently looking at acquisition/s. With verbal dexterity I did not get a clear answer. Bearing in mind the statement this morning which said no shares were to be issued for the time being to raise funds I then asked whether it would be possible for them to acquire a company in a paper transaction and if so would this technically not be issuing shares to raise funds? I very much gained the impression that this could be the case but there was no clear answer which didnt really surprise me if they had something in their sights. The easiest answer would have been no if there was no possible acquisition but there was no negative indication.

An interesting thing was that there were 2 people there who were working on raising awareness of the company, one in the US and one in Europe. I spoke to the Europe chap and gather that he has the task of getting institutional buyers. He said the main problem at the moment is that they want to see actual revenue so as the nutra money starts to come in this will be much easier. He also said that most of these companies are looking to invest a minimum of say 500,000 which is virtually impossible with a market cap of 7 million so again as the share price goes up and the Market cap grows this will be easier. There was talk about a possible institutional buyer (could have been Swiss) although I didnt quite catch whether they had bought yet or were going to perhaps Asmodeus got the info.

ADRs

This was raised in the meeting. The facility was set up by the Bank of New York and the impression gained was that it was perhaps set up by Regen more as a possible vehicle for acquisition of US companies than for trading. I pointed out that it didnt seem possible to trade them anyway and PL said he couldnt discuss it there but we would hear something soon in this respect.

Pet nutra

Sorry forgot all about this one but the impression I have gained before is that whilst this is on the to do list it is not a great revenue generator so they have more important areas on which to focus funds at present.

Final Thoughts

The overwhelming indication was that the company are very disappointed by the share price but very excited by future prospects and a number of times it was commented that they would expect to be self sustaining by 2008 possibly before depending on a Zolpidem licensing deal.

As I say there were handful of holders there and between us we asked numerous questions, sought clarification, moaned etc. Asmodeus had quite a lot of notes so will be able to fill in any gaps.

We did have a good moan about PR. I cited HML as an example of how to orchestrate PR leading up to a deal with numerous announcements of were getting closer and closer and yet closer and even now they have not yet actually said theyve signed a deal and yet their share price has gone up about 500% during this process. Regen who actually have sigend a deal seemed to throw out an RNS on a Thursday which was not particularly inspiring followed by a rushed GCPL one and our price then went down. They did seem to accept our comments although did point out that Zolpidem newspaper coverage had been good.

Another holder who was with Asmodeus had lots of great question and really gave the Directors a grilling over why they did not seem to show much faith in terms of their personal investment in the company. PL tried to defend this by saying that they dont get paid that much and they also have their employment based on the success of the company. This holder took no prisoners and said this wasnt much of a defence and he would like to see them having a bit more of a financial stake if they really are as confident as they make out. It was a point well made and would be great if we did see it acted upon as Im sure if we saw a couple of announcements about Director buying outside of share placements it would be positively received by the market.

There you have it. The market obviously hasnt made much of the interims but we have GCPL income increasing, news to come of the start of Zolpidem trials in November and perhaps about the documentary, the launch of the nutra getting nearer, people actively working on increasing awareness in Europe and the US, hopefully the sorting of the ADR facility, possible other deals to come in Europe on the nutra and longer term news on the CLN peptides. Furthermore we wait to see what why this authority was needed today when they are not looking to raise funds at this time. So theres a lot more to come.

As always, posted in good faith and as accurately as memory allows!

Gantenbrink - fantastic post. Many thanks for your time and effort. Sounds pretty good on the whole to me. A waiting game but then all good things.....

anyone know whats happening?

Rumour Maxtor, just rumour, apparently the Express says this:-

"Regen therapeutics was steady at 1.02p yesterday amid ongoing chatter that a European licensing deal was due in the next six weeks. There is also thought to be takeover interest from overseas pharma companies, and talk of a tie-up with Eirx Therapeutics, unchanged at .29p"

Not saying that it is unfounded but, at present it is just another rumour.
kim

cheers kim.

Smoke, fire? I'd be happier if the report had been in the FT rather than the Express though.....

Lots of media coverage about Zolpidem today after a UK judge refused a family's request in a right to die case where a lady is in PVS until such time as she has tried Zolpidem. Percy Lomax was on radio 4 this morning and Radio Five Live this afternoon.

There was press coverage in the Guardian and Mail as well as on the BBC website.

All in all good news for Regen if they are able to capitalise on this coverage by ensuring that Zolpidem is continually linked to Regen as a number of articles have appeared without mention of Regen. This will come down to Regens PR which to date hasn't been great but hopefully this is an area which they are improving.

I understand that the phase 2 trials are about to start in S. Africa so if they can get that announcement out now whilst there is the media interest that would be great timing and should attract some new investment as so far there is nothing in the current SP to reflect the potential of this drug.

ReGen Therapeutics PLC
07 December 2006



ReGen Starts South African Zolpidem Clinical Study in Brain Damage Conditions


After approval by the South African regulatory agency, ReGen Therapeutics Plc
('ReGen' or 'the Company') has today announced that it has started dosing
subjects in a clinical study designed to explore the effects of zolpidem in
people who have suffered brain damage.


A significant body of 'open' clinical case observations has shown that zolpidem,
a long-established drug currently marketed for the treatment of insomnia, can
normalise areas of brain dormancy secondary to a primary lesion in brain damage
conditions e.g. stroke, traumatic brain injury, vascular dementia and Bell's
palsy.


The study is a double-blind, Phase IIa 'clinical proof of concept' study in
known zolpidem responders being performed in collaboration with ReGen's
subsidiary, Guildford Clinical Pharmacology Unit Ltd., UK and investigators at
the Walko Medical Centre in Springs, South Africa where the 'antidormancy'
effect of zolpidem was first discovered. This study will compare various doses
of a new orobuccal spray formulation with an existing tablet formulation.


In view of the current interest in the UK media in the use of zolpidem in
patients in a Persistent Vegetative State (PVS) ReGen would state that no
patients in this trial are in a PVS state and all are ambulant. Full results
from this study are expected to be available around the end of March 2007.


Based on over 150 case studies worldwide the clinical effects of zolpidem have
been the restoration of consciousness, swallowing, co-ordination and motor
function after stroke and traumatic brain injury. This reversal of dormancy has
been visualised by SPECT brain scanning on dosing with zolpidem. Work is ongoing
to clarify the basis of this activity.


The clinical effect is generally proportional to the size and position of the
dormant area and correlates with drug levels in the brain/plasma. Whilst to date
these effects have been achieved with existing formulations these are less than
ideal for the new use, with sedation as a significant limiting factor.


Commenting, Percy Lomax, ReGen Chairman and Chief Executive said 'We are pleased
that we are now able to get this study underway. In addition to objectively
confirming the effects of zolpidem in a clinical trial setting, we hope it will
show that new, low dose formulations have an anti-dormancy effect but in the
absence of sedation. If this is the case this will support the development of
several new formulations that we hope will allow the full benefits of zolpidem
to be delivered to patients'.


For more information, please contact:


Andrew Marshall
Greycoat Communications
Tel: 020 7960 6007
Mobile: 07785 297111


Notes to Editors:


1. Brain dormancy is an expression used to describe an area of
the brain where the cells are not dead, but are not functioning normally.

2. Ambulant means patients who are able to walk around.

3. PVS means Persistent Vegetative State. Patients do not display any
awareness of their surroundings and are unable to communicate. Sleep
alternates with apparent wakefulness.


ReGen's thesis is that zolpidem can reverse 'dormancy' at sites removed from a
primary site of brain damage (e.g. stroke, head trauma, viral infection,
near-drowning). This thesis is derived from observations of open case clinical
studies in over 150 patients.


Thus, where those functions controlled by the dormant brain areas have been
normalised the following improvements have been seen:


Aphasia (speech cognition)
Dysarthria (word articulation)
General cognition and IQ
Ataxia (limb coordination/posture)
Hearing
Basic reflexes (swallowing and continence)


ReGen has filed a use patent for the use of zolpidem in 'dormancy'.


ReGen is now carrying out background scientific research to discover, among
other things, the precise mode of action of zolpidem in this situation. ReGen
filed in May 2006 to carry out a Phase IIa clinical trial in South Africa which,
using known zolpidem responders, is intending to show whether or not a reduction
in dosage would mean a reduction in sedation, but continue the therapeutic
efficacy. The trial is also intended to include the use of a novel orobuccal
spray.


ReGen wishes to stress that it believes the overwhelming market for this drug is
for ambulant patients and whilst it has a use in PVS this is not the main direct
audience.


Further ReGen wishes to state it does not consider it to be its place to enter
into the medical ethics debate about the use of zolpidem in PVS patients. What
ReGen is working on is a reversal of brain dormancy. The licensing of any drug
is the responsibility of the Health Authority and its use is within the doctor
patient relationship and ReGen will make no comment on that.

anyone got any news? sp on the rise

It was a great shame that Regen were not able to publicise in an RNS the fact that they along with Zolpidem were the focus of a documentary last night. It brought tears to the eyes to watch the miraculous effect of this drug and made me feel proud to be a shareholder.

I believe the programme "My shocking story" is being shown again on Saturday night on Discovery channel 520 at 10pm. Whether a holder or not it is certainly worth watching as it truly is the stuff of miracles. If the current trials go as well as is hoped then the sort of revenue that this drug could bring to Regen is potentially massive.

Just got back and slightly surprised to see such a small movement in the SP. I havent yet read what has been released but here goes for a resume of the AGM.

Firstly and on a personal level most importantly I have now actually held Colostrinin tablets in my hand. Suddenly after all the research, rumours and speculation I have actually seen and held different versions of the tablet, these being: the 100mg version that Metagenics are using to approach the retail market in the US currently packaged as NG550; a 200mg capsule for feline trials; a 600mg capsule for canine trials and a chocolate flavoured human version. Whilst there was much other positive news at the meeting for me to actually see the product was very reassuring.

Moving on. The meeting was well attended with most of Regen there including the scientists Andrew Sutton and Ralf Claus who are behind the Zolpidem story. Peter Garrod was there and Tigran as well as a number of PIs and various others amongst whom were various people connected with financial institutions.

CLN Nutra

This all seemed very positive with the long awaited news that Tox and Gmp are now sorted. Launch seems pretty definite for October. The question was asked about when we might actually see revenue and whilst this was not definitively answered because of being price sensitive information we did glean that there should be revenue coming from the manufacturing side on delivery. So whilst we probably wont know how much until we see the year end results I am expecting that perhaps in September the tap should begin to turn on in respect of first funds coming in from the nutra. Royalties will obviously follow based on sales.

Discussions are ongoing for deals elsewhere and I would not be surprised to hear more in that respect fairly soon.

There does seem to be a possible angle for use of CLN as a food additive and Regen have been approached with different ideas. I could not nail down whether this was in the immediate pipeline as they are so excited about the imminent launch of Colostrinin nutra and the results of Zolpidem that these were definitely the main areas of focus.


Pets nutra.

Trials are to begin on 1st June with results probably coming out around November. These are being carried out by Nick Mills who has a large vetinary practice in the South East and has been keen to research this for some time as I remember his name coming up in the past

Zolpidem.

We are advised that trials are going well and that the spray is definitely showing positive results. The spray is quite key as it shows faster results and by virtue of different delivery method adds further weight to the use patent. They are working with Novadel for spray delivery

Good news that the first use patent has now been granted in South Africa and is in the process elsewhere. This should be good news for those concerned about ownership.

The use patent is something I had not fully understood previously and I queried at length today just to try and be sure Id got it right as I had been hung up on the 5mg issue. Zolpidem is currently a 10 mg sleeping tablet. Regen know it works in terms of the Lazarus effect etc in many cases but needed to lose the sedative hence looking at a lower dosage.

They have sought to get a patent to prevent others producing doses of 5mg or less as they could argue they were just trying to muscle in on their area of market for at that level there is no sedative effect so why would someone want to produce it for anything other than the are Regen are researching. However my understanding today is that the use patent does not relate just to the lower dosage it relates to use at whatever dosage. So if Regen can lose the sedative effect in some way at a particular dosage then someone else could not mirror that dosage for the same use.

It was reported that there have been no safety issues in the trials so far.

Certainly speaking with Andrew Sutton he is as excited now about the effects of Zolpidem as he was last time I saw him and despite his wealth of experience in this field he is resolute about the fact that this is the biggest potential market he has ever seen. Although of course whilst he might like to think that everything is going well they are carrying out the trials for a reason and once the massive volume of data is in it will probably take a month or so to assimilate the results hence if trials are completed by end June I would therefore expect results around end July/ beginning of August. Note that the Sciencom deal is based around Zolpidem showing positive results at trial whereupon the payment will be made in Regen shares so they will be keen to get to this stage whilst the share price is still depressed as it means they will get more shares for their money.

CLN Pharma

A lot of work has been going on in this area and full results are expected in Q4 of this year. They have identified a number of peptides which have displayed positive properties in different areas and once all data is in they would look to move forward with preclinical candidates and possible licensing deals. Again Percy seemed quite excited about this area of research but the more imminent news on Zolpidem and the nutra launch overshadowed it a little.

GCPL

Order book down on this time last year although I got the impression that there might not be a huge variation in actual sales.


Funding

They will need some funding before break even but are exploring possibilities. There were a number of financial questions from 2 fairly clued up investors. To one PL said that if there were a way of raising the funds without going to the market then he would do it as like us he does not like the idea of dilution.

I did ask about consolidation and he said that his advisors had said that it was not something they would recommend at the time of the last issue. He did appreciate the concerns of the smaller investor and any such move would be made with investors best interests at heart.

There was a question relating I believe to the need for resolution 8 which I have to confess I got a little lost in the answer. I think they were basically saying that the earlier authority gave them the right to issue shares but certain rules mean they were limited in the amount they could issue in one block without coming to the market and this resolution overcame it. Bearing in mind that there were institutions represented there today I did wonder whether this might have been geared up as a way for them to buy in a big block outside of the ordinary market. I am sure there are others who will understand the intricacies of the rules a little better to shed light on this point.

When asking about funding etc I did make the point that my interpretation of the accounts was that current cash should last until Mid July. This was not allowing for any GCPL revenue and if the nutra product were to be paid in part for manufacture prior to launch then this should mean that they ought not to have to raise too much money this year for working costs. This point was not disputed but not confirmed either. I came away with the impression that they will have to raise funds prior to the end of the year but as for whether this will be an issue in normal sense or an institutional investment I could not say.

I think that has covered everything. All in all a positive meeting with a general veiled optimism about everyone connected with the company. Both Peter Garrod and Tigran seemed very happy with their investments.

Certainly this is going to be an exciting few months with lots happening which I have roughly timelined as:-

1 June Start of vetinary trials
End June Zolpidem trials end
End July/ Begin Aug - Zolpidem results
October Nutra Launch
Oct Dec Results of research in for CLN peptides & assessment of preclinical candidates
Nov - Vetinary trial results

During this time we could also hear about further nutra deals and if Zolpidem results are very positive then perhaps a deal there too.

As always, posted in good faith and to the best of my recollection and interpretation.

It was good to see a bigger turn out today and six of us had a pleasant lunch afterwards. We did not crack open the champagne today, sticking to beer and wine but hopefully next time.

Gantenbrink - thank you for such an excellent and informative synopsis of the day.

more positive news today. marketing and development leading to a good end to this year..

watcher

BE VERY CAREFUL WITH THIS ONE, I HAVE HAD IT ON MY WATCH SCREEN FOR AGES!

CHECK THE TRADING RANGE FOR THE PAST YEAR IT WILL TAKE A BOMB FOR IT TO BREAK OUT OF THAT RANGE.

I dont think its going anywhere--I trust I AM WRONG FOR THE LONG TERM HOLDER'S SAKES.

Every range is one day broken David10B - As holders we just think (and hope) it will be in the right direction.

I trust this is true for all holders queen.

Good luck, but please remember what took this to 2p a while back and how quick the bottom fell out.

A rather uninspirering day chaps-- a what!

Interesting- yesterday we heard that Regen and Metagenics appeared together promoting Colostinin at a conference in Australia sponsored by Metagenics associate company in Australia Health World. Today it seem from the link below that Metagenics Australian website is promoting Colostrinin in their "shop" section when so far the only license granted is in the US. Hopefully there is more news on the horizon:-
https://www.metagenics.com.au/shop/index.cfm?fuseaction=item&id=745

BE CAREFUL OF THE MANAGEMENT HERE!

why david

Look at the history. Check it carefully.

What's your agenda here David? You've popped up from nowhere giving an extremely one-sided view in mini-soundbites and it would be interesting for longer-term posters to this thread to know why.

No Adgenda, does one have to always have one?

Just honest comments which a rewad of the compny's histroy, cashs calls share in circulation etc will substantial.

Seems to me this company has been trying to tread water for years but is slowly sinking. I dont mean it will go bust but it should be taken over as the products are good.

That said the management lack direction.

Fair enough, thanks for your response. The products are good which is why holders have faith.

jJaguar cars are great too, but you have to get the to the punters

queen1

Do you know anything about David...if not may I suggest you do some homework on this individual, because if you do you will find out that he is very unpleasant .

On ADVFN he goes under the nickname of 10JimB and Jim_ Bentley Davis.

Good luck with RGT.

What A LOAD OF RUBBISH FORM A DISGRUNTLED UNFORTUNATE COH SHARE OWNER WHO SIMPLY COULD NOT TAKE THE EXPOSURE I GAVE HIS PET SHARE!

What a child he should be banned from all financial BBs.

Queen1 please take up the little boy's offer and do you homeworks on me, send me an email and if your are ever down in Plymstock drop by, especially if your any good at building.

BMW WHEN ARE YOU GOING TO GROW UP?

I read them all and only post here

now now you two..lets keep to the subject in hand..it seems to me that promotional exposure can only help the s.p. looking at company products and development so far.

watcher

Thanks all - I have my own "idiot" who seems to follow me around at the moment (the latest chapter in the saga is currently running on the CEN thread) so I'm happy to keep out of another one. It would be good though David if your posts could be balanced otherwise their worth may be diminished.

Good luck to all holders anyway!

queen1

Don't say I did'nt warn you.

Good luck.

Queen1, I try to balance the SP performance with time.

Conclusion RGT is not going anywhere fast.

nice to watch that strong buying pattern today..patients is a key..he he

watcher

Down I see despite all the rampings.

Be careful with this one its a money burner!

won't be down here for long if this pattern of buys continues

Even with that volume it will be difficult to shift the SP just watch.

Oh shut up David - take it somewhere else. You really are a bore.

queen1
His not far wrong there's an over-hang here the sp is hard to shift.

He may not be driver but there's something called balance: I don't like ramping and I don't like de-ramping, both in equal measure. And if you follow Mr D's posting throughout the BB's you'll see he's a de-ramper through & through.

Hi all. Not sure if you've been keeping in touch with events elsewhere but research has revealed that Colostrinin is being advertised for sale in Australia. It is now the 4th best seller on one of the sites:- http://www.quantumevolution.com.au/oscommerce/index.php

At this point there has been no official announcement from Regen about a launch. A poster elsewhere has been told that whilst Australia will now be the first launch the official date has not been reached and hence they cannot make an announcement. I, like a numberof others have placed an order and received an email to confirm it's being shipped so will be interested to see when I receive it. Certainly strikes as good news that not only is a license being sorted for another part of the world but it is actually launching sooner than the US and thus revenue is that much closer.

Meantime Zolpidem had a one page feature in the Mail yesterday and I gather was discussed on a breakfast programme today so press interest is building in advance of the trial results data being published in a few weeks time.

Elsewhere the vet trials were due to start at the beginning of June so I assume they are under way.

Following the recent issue there must still be an overhang of at least 20-30 million shares and yet Hoodless seem to be very quiet. Initially they seemed to be pushing them actively but then nothing and they are not the ones on the offer in the market. The first hurdle when some of this news does break will be to clear any overhang but things are certainly looking interesting for the near future.

In relation to the heading of this thread there is only one way RGT will rocket and that is to center of the planet.

However good luck to all you optermists who are brave enough to hold.

I bought last year at under 1p and then sold at just under 2p thats the best rake off for a few years for tis one,

When the over-hang is out of the way this will move, on my watch list.

Thanks Gantenbrink for an informative and balanced post. Potentially interesting times ahead.

Far from it Queen1 this share is not going anywhere, and if it does start to move there will be the inevitable cash call.

do us all a favour david

watcher

I f I can I most certainly will, but if in volves a restriction on my right to my opinion, then obviously I would have to refuse as there is so muchrubbish talked about this share it coulod mislead others into thinking its going places and clearl its not.

Expansion would call for further dilution.

This company need a better quality management. I know I held it for about a year. Watched it rise on a bag full of empty promises that came to nothing and then dive back.

That said I sold at the top and I did make a few bob out of it and will buy back again if I see a chance of the SP riing maybe in 2009-

Puffed-up, self-important time-waster.

Good to have balance. As for expansion this would only come if the sales of Colostrinin nutra are greater than the 2 million units that have so far been agreed for Sterling to supply. This is possible based on the initial response and communication from one of the sellers in Australia that orders have quadrupled in the last couple of days. However if 2 million units (30 days supply) are sold at what is currently 25 each so 50 million and Regen get their royalties then there should be no need for more cash as they should have it in income.

In terms of expansion of the marketing operation this doesn't cost Regen anything as it is down to Metagenics etc.

It is quite understandable that people should be a little jaundiced with the performance of the SP and the calls for cash over the past few years but the fact is that the company is still here when many others have fallen along the way and they are actually at the stage of launching a product which many thought would never happen. To move from being a Blue Sky bio to an income generating and hopefully soon a profit making business is the transition that long term holders have waited for patiently and hopefully will be rewarded accordingly. In hindsight we'd have been best to wait until now to buy rather than averaging down from higher levels but hindsight's a wonderful thing.

queen1 - 05 Jul 2007 20:13 - 161 of 162
Puffed-up, self-important time-waster.

Correct!! but you forgot to add----with a knack of calling 'em right.

I will come back a year from now and without a signifcant market penitration the SP will be as dead as it is today.

You want a pharma THEN buy MLR the next six months will be brilliant---anD remeMber you heard it here for----FREE.

queen1

He lost a fortune on BKE...but he refuses to admit it.

Yes..he is a self-important time waster and should be banned..

Still harping on. Have you not got enough on your plate worring about the falling COH?

I have asked you to prove your rantings about BKE as I keep telling you.you always manage to leave the dood open for me to come back with--I WOULD NOT TOUCH ANYTHING THAT WORTHINGTON IS INVOLVED IN YOU WOULD BE MAD TO DO SO. DIGGLE INVESTMENTS SEEMS TO BE GETTING THE CREAM.

COH down tomorrw RGT AS STAGNANT AS EVER.

Have a REALLY GREAT RESTFUL NIGHT AS TOMORROW WILL PROVE FRUSTRATING FOR YOU BOTH.

ps how the hell can you lose a fortune on BKE its a penny dreadful like all Worthigtons dabblings.

If for example one held 100000000 you would only be talking a few grand, 10K at best.

YOU REALLY ARE AN IDIOT...100,000,000(100million) is more than 10K.

YUO SHOULD BE BANNED...ABSOLUTE IDIOT.

Not at the 1p price the MMs offer for large sales of this dog share, it is not! Why not check these things out before gobbing emptily!

Far too many shares in issue whats need is a consolidation to give the company a better feel.

Chaps dont miss the MLR boat if you can.

Get in now before it flies

I'm glad my summary was correct. But haven't you got better things to do with your time in Devon than bitcing about a share you don't even own?!

Hi Queen not really as I have retired now. I look at all shares with the aim of trying to call them right.

You woud have done well if you had bought MLR WHEN I FIRST SUGGESTED IT TO YOU.

I have managed to "Puff" up my portfolio this week

Have a great day.

queen1

This insect should be banned by Ian.

Email Ian and voice your opinions and join the many other posters who have complained about him.

Now whats the matter Mr Hasbeener my prediction upsetting you?

Now if we are to revert to the school yard proactice of name calling please get it right---ITS MR INSECT PLEASE!

Queen1 I trust you bought MLR.

ps I would leave hasbeener alone to run to teachersome things never change and there are always a few in ever classroom.

You stupid old sod, you've never personally recommended anything to me. Oh I'm sorry, IT SEEMS THAT I HAVE TO SHOUT LIKE YOU DO TO MAKE MYSELF HEARD. IS IT SWITCHED ON?

queen1

Email Ian...this is abuse.

COME COME COME MY DEAR QUEEN I ONE-A STUPID OLD SOD i MAY WELL BE BUT I DID SAY THIS TO YOU:-

David10B - 05 Jul 2007 21:14 - 163 of 176

queen1 - 05 Jul 2007 20:13 - 161 of 162
Puffed-up, self-important time-waster.

Correct!! but you forgot to add----with a knack of calling 'em right.

I will come back a year from now and without a signifcant market penitration the SP will be as dead as it is today.

You want a pharma THEN buy MLR the next six months will be brilliant---anD remeMber you heard it here for----FREE.


DID YOU FORGET TO BUY OR WHAT AS IT WAS A TAD CHEAPER WHEN I "PERSONALLY RECOMMENDED" THAT TO YOU.

OH YES TODAY'S PRICE WILL LOOK EVEN CHEAPER NEXT WEEK!

IT WILL BE CHEAPER NEXT WEEK...YOU ARE CORRECT.

look cheaper you fool!

I'm actually laughing davie. You must remember to keep taking the pills.

But thanks for the recommendation. On its strength alone I will sell my house, the houses of my family, cash-in my pension, empty my savings account and plough all into this, and any other stock you may recommend. No other words are needed. Research isn't required. Davie has spoken, the word is true. All who fail to follow the word will be struck down - plague be upon your lands.

No need to be so dramic Queen 1 No Plagues, all that will happen is you wont make money and be stuck in RGT.

Such a dour, drab, disappointing response Davie. I'm happy to take my chances with RGT thanks so, for the hard-of-hearing elderly amongst us, BUTT OUT.

Come come come old boy I held these and last year advised selling at 2p which I did- MLR was then 7p I also advised putting your money from RGT into MLR THEN-

GUESS WHAT, I GOT SCOFFED AT.

GUESS WHAT, DO YOU THINK I CARE?----YOU WILL FIND THE ANSWER IN MY CHEQUE BOOK-

GUESS WHAT AGAIN. I SPEND MY TIME HEAR TO LEARN, ADVISE, EDUCATE AND ABOVE ALL TO MAKE MONEY.

last week was a good 'un for me the coffers were loaded up with gold and stuff.

queen1

He is now suffering from delusions...

Far from it hasbeener, far from it, a fat wallet maybe but never deluded--never!

And thus it was written, and from far around all were amazed. For they had heard THE word. But who would have thought that the answers lay in a cheque book far, far away.

But the answer to all and sundry will always have a base in the good old cheque book, for without it one is but s$$t on one's shoe!

And that Sir, as sad as it is---is true.

You're speaking in tongues now. Anyway, apologies to all RGT holders, let's get back to discussing the prospects for this risky but exciting little prospect!

MUCH BETTER THAN THROUGH ONE'S A$$$E

i feel a davidism coming

Not really much to say as RGT falls again today, all I can say with no witticism, is that I trust you bowed to a better researched knowledge, taking advantage and buying MLR, the screens speak for themselves.

But please dont kick yoursleves yet as its heading to 25p before taking a pause, the next company annoucement will send it yet even higher.

"Not really much to say as RGT falls again today" - Calamity. In a falling market the share lost 0.003p. So what??!!

And for goodness sake, this is the RGT thread so take your MLR crap somewhere else!!

now now queenie keep your shorts on, not all stocks fell today.

I suggest you look over RGT trading ranges for the past year.

Once again, you suggest. I'll tell you what Davo. When I want your suggestions how about I ask for them. Because otherwise, I really am not interested in anything you have to say. Period.

Good morning queen1.Thank you for your reply.

However, I feel that BBs are here for discussion, do you not think so?

Besides its educational to understand why some people buy certain shares, and not others

Many years ago when doing training an old experienced teacher said---never close you mind to anything.

We all know what we know, but few understand there is always stuff to learn, as no one knows it all.

I trust this helps you a little way towards enlightenment and open mindedness.

Shame they didn't teach you how to spell or construct a proper sentence.

To be honest Queen1 I have spent the last years of my life leaning how to get up people's snouts.

Starting out as an innocent young man, I soon found how easily corruptable most people are, and so fickle to boot.

I believe that all men, born equal as they may be, still need the the Sam Colt philosphy to get them through life, and most people are always looking for some excuse or other to cover up for their personal deficiencies.

Would you not agree?

What do they put in your pills at the old folks home?

Right, again, can we get this thread back on track with holders of RGT. Other, BALANCED views gratefully accepted.

Take a look at COH thread queen1, you will see you are not the only one to lock horns with David10b... Be aware that IanT is monitoring and any verbal abuse might end up with someone being banned... The only thing I would suggest is use the squelch function... Regards.

But queen1 that not very nice now is it?

I only seek to point out, perhas to the lesser informed than you, that RGT has been in steady freefall for the past five years and had numerous cash calls inbetween

Now surely you would not deny that information to potential shareholders would you.

We are, after all, just struggling to make a few bob, and we should help each other to get ahead, should we not.

Problem we all face on these BBs, is that there are far too many hidden adgendas, ramping, pumping and dumping etc.

All makes life hard for the small investors.

imo, another of these mini-minoows that is best left alone, but if you are already invested, then plenty of room at the altar rail to ask for salvation!

i post a couple of charts for you, and it is not pretty ...... the 3 month chart is just to highlight the closeness of 25+50+200 dma, all of which are likely to pose resistance the 200 dma in particular ...... the longer term one (3 year) illustrates the steady decline to virtually an all time low

Media comment, click HERE

ReGen Therapeutics said the clinical study to explore the effects of zolpidem in people who have suffered brain damage confirmed that a novel formulation of zolpidem is non-sedating.

The company said the phase IIa study to explore the 'antidormancy' effect of zolpidem was conducted on twenty patients having various debilities as a consequence of brain damage.

A dose of 2.5 milligrams caused no more sedation than placebo, suggesting the possibility that repeated 2.5 mg spray doses will show efficacy without undue sedation, ReGen said. 'Based on these results we now have the confidence to continue the development of novel zolpidem formulations for the treatment of brain dormancy2,' chairman and chief executive Percy Lomax said.

Recent 'happenings' in ReGen:-

01 October 2007
ReGen's Cognitive Nutraceutical Colostrinin TM Launched in USA

ColostrininTM to be active ingredient in Metagenics' CogniSureTM, a product
being marketed as support for the maintenance of mental capacity

ReGen Therapeutics Plc (London) announced today that its licensee Metagenics,
Inc. has launched its cognitive nutraceutical, ColostrininTM, onto the US
market. Metagenics Inc. is a leading supplier of natural medicines to healthcare
professionals.

ColostrininTM is the active ingredient in Metagenics' healthy cognition support
formula, CogniSureTM. Initially CogniSureTM is being made available to consumers
via Metagenics' network of approximately 30,000 healthcare professionals across
the USA. These include physicians, chiropractors, acupuncturists, nutritionists,
and other healthcare professionals with a specific interest in nutritional
supplementation. The product is being made available as chocolate flavour
chewable tablets in blister packs containing 30 tablets. Further details of
availability are provided on Metagenics' website
www.metagenics.com

26 October 2007
Capital Consolidation


The Board believes that it is appropriate to prepare a reorganisation of the
Company's share capital involving the consolidation of the number of Existing
Ordinary Shares. The consolidation would reduce the total number of shares in
issue, simplify trading and settlement and also facilitate a more appropriate
trading price range for the shares. The Board believes that its presentations to
the US investment community over the last three and a half years have been well
received. Unfortunately, the current low level of the share price is a block on
US investment. The Company has an American Depository Receipt (ADR), which it
proposes to list on the OTCQX market in New York. This newly established trading
facility already includes a number of well-known European company stocks. The
Board considers that a higher underlying share price is necessary for this
listing to be a success.


It is proposed that every one hundred (100) Existing Ordinary Shares, currently
having a nominal value of 0.1p each, be consolidated into one New Ordinary Share
having a nominal value of 10p each.

29 October 2007

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to
which voting rights are attached (ii):

ReGen Therapeutics Plc

2. Reason for the notification:

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation (iii):

Barclays PLC

4. Full name of shareholder(s) (if difference from 3):

Barclays Stockbrokers Ltd
Gerrard Investment Management Ltd

5. Date of the transaction and date on which the threshold is crossed or
reached (v):

25 October 2007

6. Date on which issued notified:

26 October 2007

7. Threshold(s) that is/are crossed or reached:

5% to 6%

8. Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code GB0004468319

Situation Previous to the triggering transaction (vi) -
Number of Shares 61,417,949
Number of Voting Rights (viii) 61,417,949

Resulting situation after the triggering transaction (viii) -
Number of Shares 61,980,949
Number of Voting Rights - Direct (x) N/A
Number of Voting Rights - Indirect (xi) 61,980,949
% of voting rights - Direct N/A
% of voting rights - Indirect 6.04

Perhaps we can now see a bit of positive movement in the SP. The BBC have a 45 min programme following 3 parents of coma victims to South Africa to see if Zolpidem could work for their daughters. The One Life documentary"The Waking Pill" will be shown on BBC One on Wednesday (October 31) at 10.40pm (times may vary by region).

ReGen Therapeutics said it has entered into a equity credit facility agreement of up to 2 mln stg with Duke Holdings Corp Ltd to provide a drawdown of capital in exchange for shares in the company.

The company said the initial facility of 2 mln stg is available in two tranches of 1 mln stg and that it has now issued a notice of an initial drawdown of up to 400,000 stg of shares, which may be split over a number of allotments to Duke.

ReGen also said has raised 204,648 stg before expenses by placing, directly and through its new broker Alexander David Securities Ltd, 629,685 shares at 32.5 pence each with existing investors. The company said it will use the funding to develop opportunities in the pharmaceutical sector 'in very uncertain financial market conditions.'

Executive Chairman Percy Lomax commented: 'As sales of CogniSure build up, ultimately the directors believe the company will become self financing; however the company is not yet at this point.'

Double figures gain today:

ReGen Therapeutics said it is sees market value of about $2.2 million in the first-half from the Colostrinin/CogniSure drug ordered by Metagenics Inc. based on the number of kilos ordered and assuming all are sold.